Clinical Trials on Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

Total 2126 results

University of Arizona

Recruiting

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Heinrich-Heine University, Duesseldorf
University Hospital of Cologne

Recruiting

CIRCULATing Biomarkers for Individualized Surgical Therapy in gastroEsophageal Cancer - Phase 1 (CIRCULATE1)

Cancer of Esophagus | Esophagogastric Junction Disorder

Germany
ImmunoGen, Inc.

Withdrawn

huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas

Stomach Neoplasms | Metastatic or Locally Advanced Gastric Cancer | Metastatic or Local Advanced GE Junction Cancer

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Metastatic Pancreatic Carcinoma | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer... and other conditions

United States
Northern Jiangsu People's Hospital

Completed

A 3-Arm Study Comparing the Efficacy of Anti-Reflux Reconstruction Protocols After Laparoscopic Proximal Gastrectomy

Anti-Reflux Alimentary Reconstruction | Laparoscopic Proximal Gastrectomy | Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction

China
BioInvent International AB

Active, not recruiting

BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST)

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast Cancer

Spain, United Kingdom, Germany
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

Gastric Cancer | Gastroesophageal Junction Cancer

United States, Belgium, Brazil, Canada, Chile, China, Estonia, France, Germany, Guatemala, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Philippines, Poland, Russian Federation, Singapore, Taiwan, Ukraine, United...
Pfizer

Active, not recruiting

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

Breast Neoplasms | Colorectal Cancer | Metastatic HER2+ Advanced Breast Cancer | Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)

China
Baylor College of Medicine

Recruiting

A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer (TOGAR)

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Nanfang Hospital of Southern Medical University

Recruiting

Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
European Organisation for Research and Treatment...

Withdrawn

Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) (MEGAN)

Metastatic Disease | Esophagogastric Adenocarcinoma | No Previous Chemotherapy for Metastatic Esophagogastric Cancer
Hospices Civils de Lyon

Recruiting

Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (IMMUNOGAST)

Gastric Adenocarcinoma | Metastatic Gastric Cancer | Advanced Gastric Carcinoma | Metastatic Adenocarcinoma

France
Yonsei University

Not yet recruiting

Phase II Study of Pembrolizumab (Keytruda®) and Trifluridine/Tipiracil (Lonsurf®) With Previously Treated Advanced Gastric Cancer

Gastric and Gastroesophageal Junction Adenocarcinoma
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Gastric Cancer | Gastroesophageal Junction Cancer

China
Xiaofeng Chen

Recruiting

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Akeso
Akeso Pharmaceuticals, Inc.

Active, not recruiting

A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarcinoma

Gastric Adenocarcinoma | Advanced Solid Tumors | Gastroesophageal Junction Adenocarcinoma

China
Ascenta Therapeutics

Terminated

An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

Locally Advanced Esophageal or GE Junction Cancer

United States
University Hospital Tuebingen

Unknown

Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors

Gastric Cancer | Colorectal Cancer | Cholangiocarcinoma | Pancreatic Ductal Adenocarcinoma | Esophagus Cancer | Adenocarcinoma of the Esophagogastreal Junction
Leap Therapeutics, Inc.
Merck Sharp & Dohme LLC

Completed

A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab (P102)

Esophageal Neoplasms | Gastric Adenocarcinoma | Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma | Gastroesophageal Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Gastric Cancer | Esophageal Cancer | Adenocarcinoma of the Gastroesophageal Junction

United States
Toray Industries, Inc

Recruiting

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States, Japan
Tarveda Therapeutics

Recruiting

PEN-866 in Patients With Advanced Solid Malignancies

Neoplasms | Carcinoma | Small Cell Lung Carcinoma | Gastric Cancer | Pancreatic Adenocarcinoma | Solid Tumor | Gastric Adenocarcinoma | Small-cell Lung Cancer | Advanced Cancer | Pancreatic Ductal Adenocarcinoma | Adenocarcinoma of the Pancreas | Endometrial Adenocarcinoma | Squamous Cell Carcinoma of the Penis | Gastroesophageal... and other conditions

United States
Daiichi Sankyo
AstraZeneca

Recruiting

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Gastroesophageal Junction Adenocarcinoma | Gastric Cancer, Adenocarcinoma

Hong Kong, Korea, Republic of, France, United Kingdom, Spain, China, Ireland, Brazil, Japan, Singapore, Belgium, Israel, Russian Federation, Argentina, Chile, Hungary, Poland, Portugal, Taiwan, Turkey, Ukraine, Germany, Romania, Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage III... and other conditions

United States
Changhai Hospital
CARsgen Therapeutics Co., Ltd.

Unknown

Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma | Advanced Gastric Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
Sixth Affiliated Hospital, Sun Yat-sen University

Not yet recruiting

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma

China
Legend Biotech USA Inc

Recruiting

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Gastroesophageal-junction Cancer

United States
ALX Oncology Inc.
Eli Lilly and Company

Recruiting

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Gastric Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States, Spain, France, Korea, Republic of, Taiwan, United Kingdom, Japan, Singapore, Belgium, Czechia, Italy
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma

Neoplasms | Lymphoma | Adenocarcinoma | Esophagogastric Junction

Japan
Zhejiang Cancer Hospital

Recruiting

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Gastric Cancer | Colorectal Cancer | Pancreatic Adenocarcinoma | Biliary Tract Cancer | Gastroesophageal Junction Adenocarcinoma | Liver Cancer Stage IV

China
Zhou Fuxiang
Hubei Cancer Hospital; Henan Provincial People's Hospital; Huangshi Central Hospital...

Recruiting

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma

China
Renmin Hospital of Wuhan University

Completed

First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC (RENMIN-213)

Advanced Gastric Adenocarcinoma

China
Yonsei University

Completed

PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma

Advanced Gastric Adenocarcinoma

Korea, Republic of
Mendus
PPD

Terminated

A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer (ILIAD)

Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Gastroesophageal Junction Adenocarcinoma | Carcinoma, Squamous Cell of Head and Neck

United States
Henan Cancer Hospital

Recruiting

A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab

Advanced Gastric Adenocarcinoma

China
Samsung Medical Center

Completed

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

Advanced Gastric Adenocarcinoma

Korea, Republic of
Shanghai Longyao Biotechnology Inc., Ltd.
The Affiliated Hospital of Xuzhou Medical University

Recruiting

A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma

Advanced Gastric Adenocarcinoma

China
Samsung Medical Center

Completed

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
Samsung Medical Center

Completed

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
Samsung Medical Center

Completed

Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
Samsung Medical Center

Terminated

Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy

Advanced Gastric Adenocarcinoma

Korea, Republic of
European Organisation for Research and Treatment...

Terminated

Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer

Gastric Cancer | Adenocarcinoma of the Gastroesophageal Junction

Belgium, Portugal, Germany
Washington University School of Medicine
Eli Lilly and Company

Completed

Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastro-esophageal Junction Adenocarcinoma

United States
Peking University
Roche Pharma AG

Unknown

Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Advanced Gastric Cancer

China
Shanghai Zhongshan Hospital

Recruiting

A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma

Advanced Gastric Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Prognostic Stage IIIC Breast Cancer AJCC v8 | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Stage IV Lung Cancer AJCC v8 | Locally Advanced Malignant Solid Neoplasm | Locally... and other conditions

United States
Professor David Cunningham
GlaxoSmithKline; Roche Pharma AG; Cancer Research UK

Unknown

Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer (ST03)

Oesophagogastric Cancer

United Kingdom
Bristol-Myers Squibb

Withdrawn

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Stomach Cancer | Gastric Cancer | Cancer of the Stomach | Gastroesophageal Junction

Brazil, Italy, United States, Argentina, Chile, Germany, Spain, Australia, Canada, Portugal, Mexico, Romania, Colombia, Puerto Rico
University of Chicago
National Cancer Institute (NCI)

Completed

Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage IV Pancreatic... and other conditions

United States

Clinical Trials on Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations